Dear Colleague:

There are two recently licensed vaccines against serogroup B meningococcal (MenB) disease, Trumenba® (Pfizer) and Bexsero® (Novartis). Neither MenB vaccine is recommended by the Advisory Committee on Immunization Practices (ACIP) for routine use. Current ACIP guidance is that the vaccine should be used in specific high-risk populations only.

A MenB vaccine series should be administered to persons aged ≥10 years at increased risk for meningococcal disease. This includes the following:

- Persons with persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab (Solaris®)
- Persons with anatomic or functional asplenia, including sickle cell disease
- Microbiologists routinely exposed to isolates of Neisseria meningitidis
- Persons identified to be at increased risk because of a serogroup meningococcal disease outbreak

Special populations not included in the current MenB recommendations include first-year college students living in residence halls, travelers, and military recruits.

When indicated, Trumenba should be administered as a three-dose series at 0, 2, and 6 months. Bexsero should be administered as a two-dose series at 0, and 1-6 months. Depending on the MenB product used, a complete two- or three-dose series of vaccine is required for protection from serogroup B meningococcal disease. The same vaccine product should be used for all doses. There is no preference for one product over another.

Both Trumenba and Bexsero are now available for order from the Vaccines for Children (VFC) program. The vaccines are also available for private purchase from your private vaccine supplier.

For questions related to vaccine supply or the VFC program, please email us at nycimmunize@health.nyc.gov or call 347-396-2405. Thank you for your efforts in protecting New Yorkers from vaccine-preventable illnesses.

Sincerely,

Jane R. Zucker, MD, MSc
Assistant Commissioner